Personalized Therapy and Clinical Outcome for Lung Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: closed (30 June 2021) | Viewed by 2922
Special Issue Editor
Special Issue Information
Dear Colleagues,
Personalized drug treatment based on biomarker-derived evidence of molecular pathway and oncogene addiction is essential for lung cancer therapy. Recently, the development of immune-checkpoint inhibitors has dramatically altered the strategy of lung cancer treatment. Although these drugs have significantly improved the clinical outcome of lung cancer, conventional therapies such as surgery, radiation, and chemotherapy still have crucial roles. Given the development of systemic therapy, local therapy is no longer limited to early-stage cancer and can be applied to advanced cancer with oligometastasis. Systemic and/or local therapy should be ‘personalized’ considering patient’s conditions in terms of age, comorbidity, and nutrition status as well as cancer stage and biomarkers.
This Special Issue on “Personalized Therapy and Clinical Outcome for lung Cancer” aims to provide recent information based on both translational studies and clinical trials. For this purpose, we invite investigators to submit original research articles and systematic reviews that will help readers to understand and develop personalized strategies for lung cancer treatment, including systemic therapy, surgery, and radiotherapy.
Dr. Atsushi Hata
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Lung cancer therapy
- personalized therapy
- targeted therapy
- surgery
- radiotherapy
- molecular targeted drug
- biomarkers
- combination therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
